NCT05716620 is a clinical trial of MRI in Hepatocellular Carcinoma, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh.

Who is sponsoring NCT05716620?

NCT05716620 is sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh.

What drugs are being tested in NCT05716620?

Interventions in NCT05716620: MRI.

What condition does NCT05716620 study?

NCT05716620 studies Hepatocellular Carcinoma.

Is NCT05716620 still recruiting?

NCT05716620 is currently status unknown. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05716620

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients

Status unknown Last updated 8 February 2023

What this trial tests

trial testing MRI in Hepatocellular Carcinoma in 380 participants. Status unknown.

Timeline

8 February 2022

Primary endpoint
7 February 2025

7 February 2025

Quick facts

Lead sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	380
Start date	8 February 2022
Primary completion	7 February 2025
Estimated completion	7 February 2025
Sites	1 location across India

Drugs / interventions tested

MRI — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Who can join

Adults 40 to 65, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is Utility of abbrevational magnetic resonance imaging as a screening tool for hepatocellular carcinoma in cirrhotic patients. The primary objective of the study is: • HCC detection rate of US vs AMRI in cirrhotic patients The secondary objective of the study are: * False referral rate of US vs AMRI: false referral will be defined as lack of HCC on complete MRI despite a positive US or AMRI. * Positive predictive value of US vs AMRI: The positive predictive value will be defined as the number of patients with true positive results in patients with positive US/AMRI. Participants will be evaluated by two rounds of screening 6 months apart using paired US and non-enhanced AMRI.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances and issues in imaging modalities for hepatocellular carcinoma surveillance.
Lee DH. · · 2025 · cited 5× · PMID 40007309 · DOI 10.17998/jlc.2025.02.16
Persisting challenges in the early detection of hepatocellular carcinoma.
Arvind A, Redmon K, Singal AG. · · 2025 · cited 3× · PMID 39943795 · DOI 10.1080/14737140.2025.2467184
Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection.
Park HJ, Kim DW, Choi WM, Kim SY. · · 2025 · cited 1× · PMID 40502477 · DOI 10.3348/jksr.2024.0153
Noncontrast abbreviated MRI demonstrates superior diagnostic accuracy compared to ultrasound for hepatocellular carcinoma detection: Interim results from a prospective surveillance trial.
Gupta P, Singh S, Gulati A, Mudgil P, et al · · 2026 · PMID 42113186 · DOI 10.1097/hep.0000000000001788
How to Design a Study and Write a Grant in Radiology?
Gupta P, Singhal M. · · 2025 · PMID 39802716 · DOI 10.1055/s-0044-1792077

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05716620 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Post Graduate Institute of Medical Education and Research, Chandigarh
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05716620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing